Pfizer Inc. got some rare good news out of Alabama in June, when the state's high court agreed to revisit its controversial ruling that brand-name drug companies can be held liable for injuries caused by generic versions of their drugs manufactured by third parties.
In a one-paragraph order, the Alabama Supreme Court agreed to hold an oral argument later this year in Weeks v. Wyeth, a personal injury case involving a generic version of gastric reflux drug Reglan made by Pfizer subsidiary Wyeth LLC. The order suggests that the court may be rethinking its earlier ruling that Wyeth can be named as a defendant in the Weeks case, even though the company didn't manufacture the generic Reglan tablets ingested by the plaintiff.
